Miron (Cilastatin, Imipenem)

Imipenem/cilastatin, the active ingredient in Miron, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, skin and soft tissue infections, and septicemia in hospitalized patients.

GNH USA supplies Miron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imipenem/cilastatin is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections.

Complicated intra‑abdominal infections: provides bacterial eradication in the peritoneal cavity. Complicated urinary tract infections: clears resistant uropathogens. Nosocomial pneumonia: treats hospital‑acquired lung infections. Skin and soft tissue infections: resolves deep tissue bacterial involvement. Septicemia: controls bloodstream infection.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery or loose. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in hepatic transaminases. - Injection site pain: discomfort at the infusion site. - Headache: mild tension‑type headache.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Clostridioides difficile colitis: antibiotic‑associated colitis. - Thrombophlebitis: inflammation of the vein used for infusion. - Renal impairment: worsening kidney function. - Neutropenia: marked reduction in neutrophil count.

Careful assessment and monitoring are required before and during therapy.

Renal function: adjust dose in patients with impaired renal clearance. History of seizures: monitor for neurotoxicity and avoid high doses. Allergic reactions: avoid if known hypersensitivity to carbapenems. Pregnancy and lactation: use only if benefit outweighs potential risk. Concomitant valproic acid: may reduce serum valproate levels. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin may interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Valproic acid: reduces serum concentration of valproate, risking seizure breakthrough. - Other carbapenems: additive neurotoxic potential, especially seizures. - Probenecid: may increase imipenem plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: heightened risk of nephrotoxicity. - Aminoglycosides: combined renal toxicity potential. - NSAIDs: may further impair renal function when used together.